X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Irvine Scientific Increases Production Capacity of Dry Powder Media for Cell Culture

Yuvraj_pawp by Yuvraj_pawp
26th September 2017
in Americas, News

Irvine Scientific, a world leader in cell culture media development and manufacturing today announced the expansion of its manufacturing facility in Santa Ana, California to increase overall dry-powder production capacity. The expansion was multistep and included: more space dedicated to its animal component free (ACF) dry powder production area, additional impact milling capacity, the addition of a large-scale, pharmaceutical grade blender, and higher throughput cleaning capacity of the ACF dry powder portion of the facility. As one of its fundamental business offerings, Irvine Scientific performs large-scale cGMP manufacturing of dry powder media for the biopharmaceutical, vaccine and cell therapy industries. The expansion provides tumble blending capacity of 12,000 L total dry volume. This additional capacity enables the company to provide customers with homogeneous, high-quality powder media in single production batch sizes of up to 7,000 kg.

The new large-scale blender is based on the same proven, tumble blending technology Irvine Scientific currently uses, which protects delicate raw materials and produces extremely reproducible results. The enhanced cleaning capacity is performed using a closed-loop, wash-in-place system that minimizes the risk of environmental or carry-over contamination between batches.

Rigorous testing and cGMP validation studies have been conducted to ensure media produced in the largest batch sizes possible meet the same high quality standards Irvine Scientific currently delivers to its customers. As a critical element of media quality, blend homogeneity, was proven by measuring the percent relative standard deviation (% RSD) of component concentrations in multiple batch sizes from powder samples taken from various locations in the blender. Homogeneity in the largest batch sizes was <6% RSD during validations which demonstrates that the powder homogeneity in the new blender meets the same high-performance standards previously established by existing Irvine Scientific powder manufacturing processes.

 

“We are excited about the capacity this provides our customers. With this addition, the identical continuous impact milling and blending technology in place at our two manufacturing plants, we can offer demonstrated scalability of powder manufacturing from as little as 6 kg in our Express Media Service™ group, to cGMP production lots now up to 7,000 kg. Minimizing variation between lots, keeping production costs down, and fast delivery times of final product are key requirements for our customers. Increasing our production batch capacity up to 7,000 kg will help us meet these requirements.” said Tim Mullane, COO, Irvine Scientific. “Our long-term growth and capital investment strategy are designed to keep pace with the predicted increases in demand for high quality cell culture media now and in the future.”

For more information visit http://www.irvinesci.com


About Irvine Scientific
Irvine Scientific, a member of JXTG Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years, Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

 

Media contacts
Lori Serles, Irvine Scientific
Phone: 949-261-7800 x145
Email: lserles@irvinesci.com

 

Lorna Cuddon, Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

Tags: America
Previous Post

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship to further upgrade its state-of-the-art production process for TriMix mRNA immunotherapies

Next Post

Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In